Clinical efficacy of vericiguat in the treatment of acute decompensated heart failure and its effects on LVEF of patients with different LVDd
- ZHONGGUO YAOFANG Vol. 35, Issue 11, Pages: 1374-1379(2024)
- 作者机构：
安徽医科大学安庆医学中心（安庆市立医院）心血管内科，安徽 安庆 246003
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.11.16
CLC： R969.4Received：06 November 2023，
Revised：2024-05-22，
Accepted：23 May 2024，
Published：15 June 2024
- 稿件说明：
移动端阅览
章礼玲,顾崇怀,乔锐,等.维立西呱对急性失代偿心衰的疗效及对不同LVDd患者LVEF的影响[J].中国药房,2024,35(11):1374-1379.
ZHANG Liling,GU Chonghuai,QIAO Rui,et al.Clinical efficacy of vericiguat in the treatment of acute decompensated heart failure and its effects on LVEF of patients with different LVDd[J].ZHONGGUO YAOFANG,2024,35(11):1374-1379.
章礼玲,顾崇怀,乔锐,等.维立西呱对急性失代偿心衰的疗效及对不同LVDd患者LVEF的影响[J].中国药房,2024,35(11):1374-1379. DOI： 10.6039/j.issn.1001-0408.2024.11.16.
ZHANG Liling,GU Chonghuai,QIAO Rui,et al.Clinical efficacy of vericiguat in the treatment of acute decompensated heart failure and its effects on LVEF of patients with different LVDd[J].ZHONGGUO YAOFANG,2024,35(11):1374-1379. DOI： 10.6039/j.issn.1001-0408.2024.11.16.
摘要
目的
2
观察维立西呱治疗急性失代偿心衰（HF）的临床疗效及其对不同左室舒张末期内径（LVDd）患者左室射血分数（LVEF）的影响。
方法
2
选取2022年9月至2023年5月在安庆市立医院住院的经静脉注射利尿剂或扩血管药物治疗病情稳定后予以维立西呱口服的急性失代偿HF患者，共52例。收集患者临床基线数据，记录并分析其治疗后1、6个月的血肌酐（Scr）、估算肾小球滤过率（eGFR）、N末端B型脑钠肽前体（NT-proBNP）、超声心动图指标（LVEF、
<math id="M1"><mi mathvariant="normal">L</mi><mi mathvariant="normal">V</mi><mi mathvariant="normal">D</mi><mi mathvariant="normal">d</mi></math>
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553625&type=
2.28600001
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553626&type=
8.12800026
）、堪萨斯城心肌病调查问卷（KCCQ）评分等。按是否为扩张型心肌病分为2个亚组，比较两亚组的基线数据；采用混合效应模型分析全人群和两亚组患者上述随访指标的变化情况。
结果
2
扩张型心肌病组患者的年龄显著小于非扩张型心肌病组，同时前者合并冠心病的患者比例更低、LVDd更长、LVEF水平更低、射血分数降低的HF患者更多（
P
＜0.05）。与基线值相比，治疗后1个月时，全人群、非扩张性心肌病组和扩张型心肌病组患者的KCCQ评分均显著升高（
P
＜0.001）；治疗后6个月时，全人群在KCCQ评分提升和lg（
<math id="M2"><mi mathvariant="normal">N</mi><mi mathvariant="normal">T</mi></math>
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553627&type=
2.28600001
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553628&type=
4.31799984
-
<math id="M3"><mi mathvariant="normal">p</mi><mi mathvariant="normal">r</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">N</mi><mi mathvariant="normal">P</mi></math>
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553640&type=
2.87866688
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553615&type=
10.41399956
）水平下降方面的差异均有统计学意义（
P
＜0.05）；两亚组患者的lg（NT-proBNP）水平均显著下降，KCCQ评分均显著升高（
P
＜0.05），但组间比较差异无统计学意义（
P
＞0.05）；两亚组患者的LVEF水平均显著提升（
P
＜0.05），且组间差异幅度达7.52%（
P
＝0.030）。混合效应模型结果显示，患者是否患有冠心病以及不同基线
<math id="M4"><mi mathvariant="normal">L</mi><mi mathvariant="normal">V</mi><mi mathvariant="normal">D</mi><mi mathvariant="normal">d</mi></math>
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553625&type=
2.28600001
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553626&type=
8.12800026
水平均有可能影响随访LVEF水平，其中冠心病对随访LVEF的提升有促进作用（
P
＝0.043），但是冠心病分组×时间的交互作用不显著（
P
＞0.05）；与基线
<math id="M5"><mi mathvariant="normal">L</mi><mi mathvariant="normal">V</mi><mi mathvariant="normal">D</mi><mi mathvariant="normal">d</mi></math>
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553625&type=
2.28600001
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553626&type=
8.12800026
≥62 mm相比，基线
<math id="M6"><mi mathvariant="normal">L</mi><mi mathvariant="normal">V</mi><mi mathvariant="normal">D</mi><mi mathvariant="normal">d</mi></math>
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553625&type=
2.28600001
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553626&type=
8.12800026
≤61 mm患者的LVEF提升速度更快（
P
＜0.05）。
结论
2
维立西呱能够改善急性失代偿HF患者的心功能，提高其生活质量，且不会对患者肾功能产生负面影响。该药对基线
<math id="M7"><mi mathvariant="normal">L</mi><mi mathvariant="normal">V</mi><mi mathvariant="normal">D</mi><mi mathvariant="normal">d</mi></math>
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553625&type=
2.28600001
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553626&type=
8.12800026
≤61 mm的患者，尤其能够显著提升其LVEF水平。
Abstract
OBJECTIVE
2
To observe the efficacy of vericiguat in the treatment of acute decompensated heart failure （HF） and its effect on left ventricular ejection fraction （LVEF） in patients with different left ventricular end-diastolic internal diameters （LVDd）.
METHODS
2
A total of 52 patients with acute decompensated HF who were hospitalized in Anqing Municipal Hospital from September 2022 to May 2023 and were stabilized by intravenous injection of diuretics or vasodilators and then given vericiguat orally were selected. Clinical baseline data were collected， and blood creatinine （Scr）， estimated glomerular filtration rate （eGFR）， N-terminal pro-B-type natriuretic peptide （NT-proBNP）， echocardiographic indexes（LVEF， LVDd）， and Kansas City cardiomyopathy questionnaire （KCCQ） scores and so on were recorded and analyzed at 1 and 6 months after treatment. The patients were divided into two subgroups according to whether they had dilated cardiomyopathy or not， the baseline data were compared between the two subgroups， and the changes in the above follow-up indexes for the entire population and two subgroups of patients were analyzed by using mixed effect model.
RESULTS
2
Patients in the dilated cardiomyopathy group were significantly younger than those in the nondilated cardiomyopathy group， while the former had a lower proportion of patients with combined coronary artery disease， longer LVDd， lower LVEF levels， and more HF patients with reduced ejection fraction （
P
＜0.05）. Compared with baseline values， KCCQ scores were significantly higher in patients in the whole population， non-dilated cardiomyopathy group and dilated cardiom
yopathy group at 1 month after treatment （
P
＜0.001）. The difference between the whole population in terms of elevated KCCQ scores and decreased lg（
<math id="M8"><mi mathvariant="normal">N</mi><mi mathvariant="normal">T</mi></math>
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553627&type=
2.28600001
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553628&type=
4.31799984
-
<math id="M9"><mi mathvariant="normal">p</mi><mi mathvariant="normal">r</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">N</mi><mi mathvariant="normal">P</mi></math>
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553640&type=
2.87866688
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553615&type=
10.41399956
） levels was statistically significant at 6 months after treatment （
P
＜0.05）； the levels of lg（
<math id="M10"><mi mathvariant="normal">N</mi><mi mathvariant="normal">T</mi></math>
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553627&type=
2.28600001
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553628&type=
4.31799984
-
<math id="M11"><mi mathvariant="normal">p</mi><mi mathvariant="normal">r</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">N</mi><mi mathvariant="normal">P</mi></math>
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553640&type=
2.87866688
https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=90553615&type=
10.41399956
）of two subgroups were significantly decreased and KCCQ scores were significantly increased （
P
＜0.05）， but the difference was not statistically significant （
P
＞0.05）； LVEF levels of the patients in both subgroups were significantly elevated （
P
＜0.05） and the difference between the subgroups amounted to 7.52% （
P
＝0.030）. Mixed effect model result showed that whether patients had coronary artery disease and different baseline levels of LVDd were likely to affect follow-up LVEF levels， with coronary artery disease contributing to follow-up LVEF elevation （
P
＝0.043）， but the coronary artery disease subgroup × time interaction was not significant （
P
＞0.05）；compared with patients with baseline LVDd ≥62 mm， patients with baseline LVDd≤61 mm had a faster LVEF improvement （
P
＜0.05）.
CONCLUSIONS
2
Vericiguat is able to improve cardiac function and quality of life in patients with acute decompensated HF without negatively affecting their renal function. The drug is able to significantly improve LVEF levels in patients with baseline LVDd ≤61 mm.
关键词
Keywords
references
MCDONAGH T A ， METRA M ， ADAMO M ， et al . 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [J ] . Eur Heart J ， 2021 ， 42 （ 36 ）： 3599 - 3726 .
中华医学会心血管病学分会心力衰竭学组 ， 中国医师协会心力衰竭专业委员会 ， 中华心血管病杂志编辑委员会 . 中国心力衰竭诊断和治疗指南2018 [J ] . 中华心血管病杂志 ， 2018 ， 46 （ 10 ）： 760 - 789 .
The Heart Failure Group of the Cardiovascular Branch of the Chinese Medical Association ， the Heart Failure Professional Committee of the Chinese Medical Association ， the Editorial Committee of the Chinese Journal of Cardiovascular Disease . China guidelines for diagnosis and treatment of heart failure 2018 [J ] . Chin J Cardiol ， 2018 ， 46 （ 10 ）： 760 - 789 .
YAN T ， ZHU S J ， YIN X J ， et al . Burden，trends，and inequalities of heart failure globally，1990 to 2019：a se- condary analysis based on the global burden of disease 2019 study [J ] . J Am Heart Assoc ， 2023 ， 12 （ 6 ）： e027852 .
The Writing Committee of the Report on Cardiovascular Health and Diseases in China ， HU S S . Report on cardiovascular health and diseases in China 2021：an updated summary [J ] . J Geriatr Cardiol ， 2023 ， 20 （ 6 ）： 399 - 430 .
PACKER M ， ANKER S D ， BUTLER J ， et al . Cardiovascular and renal outcomes with empagliflozin in heart fai- lure [J ] . N Engl J Med ， 2020 ， 383 （ 15 ）： 1413 - 1424 .
ARMSTRONG P W ， PIESKE B ， ANSTROM K J ， et al . Vericiguat in patients with heart failure and reduced ejection fraction [J ] . N Engl J Med ， 2020 ， 382 （ 20 ）： 1883 - 1893 .
HEIDENREICH P A ， BOZKURT B ， AGUILAR D ， et al . 2022 AHA/ACC/HFSA guideline for the management of heart failure：a report of the American College of Cardio- logy/American Heart Association Joint Committee on clinical practice guidelines [J ] . Circulation ， 2022 ， 145 （ 18 ）： e895 - e1032 .
DAUBERT M A ， ADAMS K ， YOW E ， et al . NT-proBNP goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF [J ] . JACC Heart Fail ， 2019 ， 7 （ 2 ）： 158 - 168 .
中华医学会心血管病学分会 ， 中国心肌炎心肌病协作组 . 中国扩张型心肌病诊断和治疗指南 [J ] . 临床心血管病杂志 ， 2018 ， 34 （ 5 ）： 421 - 434 .
The Cardiovascular Branch of the Chinese Medical Association ， the Chinese Collaborative Group on Cardiomyositis and Cardiomyopathy . China guidelines for diagnosis and treatment of dilated cardiomyopathy [J ] . J Clin Cardiol ， 2018 ， 34 （ 5 ）： 421 - 434 .
冯国双 . 重复测量数据的常用统计分析方法 [J ] . 中华预防医学杂志 ， 2020 ， 54 （ 7 ）： 804 - 812 .
FENG G S . Statistical methods for repeated measurement data in scientific research [J ] . Chin J Prev Med ， 2020 ， 54 （ 7 ）： 804 - 812 .
GHEORGHIADE M ， GREENE S J ， BUTLER J ， et al . Effect of vericiguat，a soluble guanylate cyclase stimulator，on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction：the SOCRATES-REDUCED randomized trial [J ] . JAMA ， 2015 ， 314 （ 21 ）： 2251 - 2262 .
中国医师协会心力衰竭专业委员会 ， 国家心血管病专家委员会心力衰竭专业委员会 ， 中华心力衰竭和心肌病杂志编辑委员会 . 伊伐布雷定临床应用中国专家共识 [J ] . 中华心力衰竭和心肌病杂志 ， 2020 ， 4 （ 2 ）： 84 - 91 .
The Heart Failure Professional Committee of the Chinese Medical Association ， the Heart Failure Professional Committee of the National Cardiovascular Disease Expert Committee ， the Editorial Committee of the Chinese Journal of Heart Failure and Cardiomyopathy . Chinese expert consensus on the clinical application of ivabradine [J ] . Chin J Heart Fail Cardiomyopathy ， 2020 ， 4 （ 2 ）： 84 - 91 .
SPERTUS J A ， JONES P G ， SANDHU A T ， et al . Interpreting the Kansas City cardiomyopathy questionnaire in ClinicalTrials and clinical care [J ] . J Am Coll Cardiol ， 2020 ， 76 （ 20 ）： 2379 - 2390 .
PIESKE B ， MAGGIONI A P ， LAM C S P ， et al . Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction：results of the soluble guanylate cyclase stimulator in heart failure patients with Preserved EF （SOCRATES-PRESERVED） study [J ] . Eur Heart J ， 2017 ， 38 （ 15 ）： 1119 - 1127 .
BALZER M S ， PAVKOVIC M ， FREDERICK J ， et al . Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution [J ] . Cell Rep Med ， 2023 ， 4 （ 4 ）： 100992 .
BÉNARDEAU A ， KAHNERT A ， SCHOMBER T ， et al . Runcaciguat，a novel soluble guanylate cyclase activator，shows renoprotection in hypertensive，diabetic，and metabolic preclinical models of chronic kidney disease [J ] . Naunyn Schmiedebergs Arch Pharmacol ， 2021 ， 394 （ 12 ）： 2363 - 2379 .
0
Views
730
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
